Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
PainReform ( (PRFX) ) has shared an announcement.
PRF Technologies Ltd., a Nasdaq-listed clinical-stage specialty pharmaceutical and technology company, develops extended-release drug-delivery solutions for post-operative pain and operates the DeepSolar platform for AI-driven energy optimization in solar-integrated settings. Through majority-owned LayerBio, PRF is building an ophthalmic drug-delivery platform intended to expand into multiple ocular indications, complementing its broader focus on healthcare and sustainable energy technologies.
On April 28, 2026, PRF Technologies announced that the U.S. Food and Drug Administration had cleared its Investigational New Drug application for OcuRing-K, enabling a Phase II clinical trial in cataract surgery patients in the United States. The bio-erodible intraocular ketorolac ring is designed as a drop-less, sustained-release therapy to manage post-cataract pain and inflammation, potentially simplifying recovery and improving adherence, and PRF expects this milestone to advance its ophthalmic strategy while creating a new long-term value driver alongside its DeepSolar energy platform.
Following the April 28 clearance, the company plans to launch a multi-center Phase II trial in the U.S. after startup activities, with patient enrollment targeted for the second half of 2026 and endpoints focused on pain reduction, inflammation control, and safety. Given the high global volume of cataract surgeries and the burdensome eye-drop regimens that currently dominate post-operative care, successful development of OcuRing-K could strengthen PRF’s competitive position in ocular therapeutics and enhance the commercial prospects of its LayerBio-based ocular delivery platform.
Spark’s Take on PRFX Stock
According to Spark, TipRanks’ AI Analyst, PRFX is a Neutral.
The score is primarily held down by very weak financial performance (minimal revenue, large losses, and ongoing cash burn), with only the low-debt balance sheet offering a partial offset. Technicals are mixed but still unfavorable on longer-term trend measures, and valuation support is limited due to negative earnings and no dividend.
To see Spark’s full report on PRFX stock, click here.
More about PainReform
PRF Technologies Ltd., listed on Nasdaq as PRFX, is a clinical-stage specialty pharmaceutical company focused on reformulating established therapeutics for post-operative pain management and developing AI-driven energy optimization software via its DeepSolar platform. Through proprietary extended-release drug-delivery systems and advanced energy analytics, the company targets high-impact sectors including healthcare and sustainable, solar-integrated energy environments.
The firm’s pharmaceutical programs aim to provide prolonged post-surgical pain relief while reducing dosing frequency and reliance on opioids, and its majority-owned subsidiary LayerBio, Inc. underpins a growing ophthalmic drug-delivery franchise. In parallel, DeepSolar offers tools for consumers and enterprises to monitor, forecast, and optimize energy consumption, positioning PRF as a diversified technology player across life sciences and clean energy markets.
Average Trading Volume: 708,920
Technical Sentiment Signal: Strong Sell
Current Market Cap: $1.93M
See more data about PRFX stock on TipRanks’ Stock Analysis page.